On August 27, 2018 ImmunoGen, Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, reported that the following presentations by Company management at upcoming investor conferences will be webcast (Press release, ImmunoGen, AUG 27, 2018, View Source [SID1234529086]):

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

20th Annual Rodman & Renshaw Global Investment Conference, sponsored by H.C. Wainwright & Co., LLC September 5 at 12:30pm ET

Morgan Stanley 16th Annual Global Healthcare Conference September 13 at 3:30pm ET

A webcast of each presentation will be accessible live through the "Investors" section of the Company’s website, www.immunogen.com; a replay will be available in the same location for approximately two weeks.

On August 27, 2018 Generex Biotechnology Corporation (www.generex.com) (OTCQB:GNBT) (View Source) reported to announce that Richard Purcell, the Company’s Executive Vice President of Research & Development will participate in a panel discussion at the Cambridge Healthtech Institute’s Immuno-Oncology Summit at the Seaport World Trade Center in Boston, MA (https://www.immuno-oncologysummit.com/) on August 30, 2018. The panel discussion will focus on current trends and future prospects for immunotherapy in the treatment of cancer. Additionally, Mr. Purcell will provide an overview of the relaunched clinical development program of the HER2/neu immunotherapeutic vaccine, AE37, together with strategies to advance the proprietary Ii-Key technology under development at the Company’s wholly-owned subsidiary, Antigen Express, Inc. (www.antigenexpress.com).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"The introduction of checkpoint inhibitors has been revolutionary in the practice of clinical oncology, but is only effective in roughly 30% of patients across a variety of cancers," said Mr. Purcell. "The complementary mechanism of action of AE37 (T-cell activation), and encouraging results obtained in triple negative breast cancer patients, strongly suggest that the combined use of AE37 with pembolizumab (Keytruda) will provide significantly greater efficacy than either alone."

The Immuno-Oncology Investing & Partnering Forum is taking place on Thursday, August 30th and the session Novel Therapeutics in Cancer Immunotherapy will take place at 1:30 pm EDT and consist of company presentations followed by Q&A with the audience. The conference is taking place at the Seaport World Trade Center in Boston, MA, and the session room is Beacon Hill 1

On August 27, 2018 Bio-Path Holdings, Inc., (NASDAQ: BPTH), a biotechnology company leveraging its proprietary DNAbilize antisense RNAi nanoparticle technology to develop a portfolio of targeted nucleic acid cancer drugs, reported it has commenced Stage 2 of the company’s Phase 2 trial of prexigebersen in acute myeloid
leukemia (Press release, Bio-Path Holdings, AUG 27, 2018, View Source [SID1234529151]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The open-label Phase 2 study is evaluating the efficacy and safety of prexigebersen in conjunction with LDAC, a therapeutic regimen well established in treatment of AML patients who cannot or elect not to be treated with more intensive chemotherapy. The primary objective of the study is to determine whether the combination of prexigebersen and LDAC provides greater efficacy than would be expected with LDAC alone in this de
novo patient population.

"We are delighted to announce the expansion of our ongoing Phase 2 clinical trial of prexigebersen for the treatment of acute myeloid leukemia using a dosing schedule that administers a greater amount of prexigebersen to the patient prior to commencing LDAC dosing than in the first part of the trial. Based on compelling new data, we are also
including a cohort of patients who will be treated with a combination of prexigebersen and decitabine," said Peter Nielsen, President and Chief Executive Officer of Bio-Path. "Results from the planned interim analysis of the first part of this Phase 2 study were particularly encouraging, with 47% of treated patients demonstrating a response. Consequently, we remain enthusiastic about prexigebersen’s potential and believe these protocol changes
will optimize the drug’s impact in AML cancer patients with high unmet need."

Based on recommendations from the study’s principal investigators, the Company amended the study’s protocol to change the dosing schedule in Stage 2 to that used in the Phase 1b study in relapsed and refractory AML patients as announced in April 2018. In the Phase 1b study, a greater amount of prexigebersen was administered prior to LDAC
treatment starting at day 10 versus LDAC treatment starting on day four as was the case in Stage 1 of the current Phase 2 study. Importantly, Stage 2 of the study includes a cohort of patients treated in combination with decitabine based on relatively new and positive data with this compound. Bio-Path plans to perform an interim analysis of each cohort once approximately 19 evaluable patients are reached in the cohort.

As previously announced, a planned interim analysis of Stage 1 of the study was performed on 17 evaluable patients, with four patients achieving complete responses and four patients achieving stable disease, including one patient achieving a morphologic leukemia free state and one patient who showed significantly reduced bone marrow blasts. In total, 47% of the evaluable patients showed some form of response, including stable disease, to
the combination treatment. The average patient in Stage 1 of the study was 73.5 years of age

On August 27, 2018 Biotheus Inc. reported that it will develop innovative biomedical projects valued at 800 million yuan ($125 million) in Zhuhai with revenue expected to exceed 3 billion yuan ($469 million) once production begins (Press release, Biotheus, AUG 27, 2018, View Source [SID1234533245]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The development will be a joint effort with the Zhuhai National Hi-Tech Industrial Development Zone (Tangjiawan) Administrative Committee as stipulated in a cooperation agreement signed on Aug 23.

Biotheus is a specialized researcher of brand-new biomedicine in line with advanced international standards. Established this March in the Technological Innovation Coast, it covers 4,500 sq m (1.1 acres).

The company will research and develop a new generation of monoclonal antibodies, recombinant proteins, and peptide biopharmaceuticals. The partnership deal covers six projects seeking first-class bio drugs, including four targeting improvements in tumor immunotherapy and two looking into metabolic disease treatment.

The projects are to be implemented by a professional team with extensive experience in R&D, industrialization, and management in the biomedicine sector. Chief among them are Liu Xiaolin, CEO of the company, who was previously the senior vice president at Innovent Biologics, and Lyu Qiang, chairman of the company and an expert listed in the national Thousand Talent Program.

Researchers at Prometheus Bio-technology

Staffers involved have participated in more than 40 R&D projects, and the products resulting from their efforts now reap $20 billion in annual sales, according to a manager.

Lyu said the company hopes to lead the Pearl River Delta in contract development and manufacturing organization in biomedicine and will promote the growth of related industries.

On August 27, 2018 Delcath Systems, Inc. (OTCQB: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, reported an abstract from a study conducted in Germany of the use of the Delcath Hepatic CHEMOSAT Delivery System to treat patients with metastatic ocular melanoma with liver metastases, has been accepted for presentation as a poster at the Cardiovascular and Interventional Radiology Society of Europe (CIRSE) annual meeting (Press release, Delcath Systems, AUG 27, 2018, View Source;p=RssLanding&cat=news&id=2364903 [SID1234529755]). The abstract, Survival and Response of Patients with Metastatic Ocular Melanoma after Chemosaturation Percutaneous Hepatic Perfusion, will be presented by M. Zeile, and A. Stang, et al of the Asklepios Barmbek Clinic in Hamburg, Germany.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The CIRSE 2018 annual meeting will be held in Lisbon, Portugal September 22-25, 2018.